e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Clinical aspects in the management of sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
O. Baranova, O. Baklanova, V. Voinov (St. Petersburg, Russian Federation)
Source:
Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Session:
Clinical aspects in the management of sarcoidosis
Session type:
Thematic Poster Session
Number:
3450
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Baranova, O. Baklanova, V. Voinov (St. Petersburg, Russian Federation). The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS). Eur Respir J 2008; 32: Suppl. 52, 3450
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 85s
Year: 2007
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Use of surfactant-BL (S-BL) in complex treatment of pulmonary TB patients
Source: Eur Respir J 2003; 22: Suppl. 45, 521s
Year: 2003
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up)
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010
Isophonum usage in treatment of patients with pulmonary tuberculosis and accompanying pathology and elderly patients
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD)
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007
The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 72s
Year: 2006
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 713s
Year: 2004
Effectiveness of pulmonary rehabilitation including occupational therapy (OT) on the prognosis of patients with COPD
Source: Annual Congress 2012 - New adjuncts and modalities in pulmonary rehabilitation
Year: 2012
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Do results of T-SPOT.TB assays change during and after treatment of active tuberculosis?
Source: Annual Congress 2006 - New methods to diagnose tuberculosis infection
Year: 2006
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept